Core Viewpoint - AIM ImmunoTech Inc. announced a stock dividend of one share for every 1,000 shares of outstanding common stock and for every outstanding option or warrant that has a right to receive stock dividends, with the record date set for January 9, 2026, and distribution on January 13, 2026 [1]. Group 1: Stock Dividend Details - The stock dividend will be issued to stockholders and holders of Alternate Securities, with fractional shares rounded down and cash distributed for any remaining fractions based on a share price of $1.305, the average price on December 29, 2025 [2]. - Stockholders will not need to take any action to receive the stock dividend, as their accounts will be credited automatically, and brokers will receive the additional shares on behalf of stockholders [3]. Group 2: Company Overview - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19, with its lead product being Ampligen (rintatolimod), a first-in-class investigational drug [4].

As filed with the Securities and Exchange Commission on December 11, 2025 Registration No. 333-____________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Thomas K. Equels Chief Executive Officer AIM ImmunoTech Inc. 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 (Name, address, including zip code, and tele ...

Core Insights - AIM ImmunoTech will participate in the Virtual Investor Closing Bell Series on December 4, 2025, featuring CEO Thomas K. Equels [1] - The discussion will focus on AIM's clinical and regulatory strategy for its lead drug Ampligen, particularly the DURIPANC clinical trial in collaboration with AstraZeneca for metastatic pancreatic cancer [2] - The importance of a completed Phase 2 clinical trial with Merck, showing the combination of Ampligen and Keytruda was well-tolerated and beneficial for advanced recurrent ovarian cancer, will also be highlighted [2] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator [4]

Core Insights - AIM ImmunoTech Inc. presented data from a Phase 2 clinical study on Ampligen for advanced recurrent ovarian cancer, showing promising results at the 40th Annual SITC Meeting [1][2] Study Results - The study involved 27 platinum-sensitive patients, with 24 evaluable for response; 5 achieved complete response and 7 had partial response, resulting in an Objective Response Rate (ORR) of 50% [2] - This ORR is significantly higher compared to previous studies, such as Keynote-100, which reported ORRs of 7.4% and 9.9% for pembrolizumab alone [2] Mechanism and Potential - AIM believes that Ampligen can act synergistically with checkpoint inhibitors, potentially benefiting patients who do not respond to these therapies alone [3] - The study's findings suggest that Ampligen may enhance traditional cancer treatments, improving immune responses and prolonging remission for patients with limited options [4] Intellectual Property - AIM holds several patents related to the use of Ampligen in combination with checkpoint inhibitors, with expiration dates ranging from 2039 to 2040 in various jurisdictions [5] Company Overview - AIM ImmunoTech Inc. focuses on developing therapeutics for cancers, immune disorders, and viral diseases, with Ampligen as its lead investigational drug [7]

Core Insights - AIM ImmunoTech Inc. announced that data from its Phase 2 clinical study on cisplatin-resistant advanced recurrent ovarian cancer using Ampligen (rintatolimod) was accepted for presentation at the 40th Annual SITC Meeting [1] - The study focuses on a combination locoregional chemoimmunotherapy approach and its correlation with clinical outcomes [1] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator [2]

Core Insights - AIM ImmunoTech Inc. has been granted a European patent for its proprietary dsRNA compositions aimed at treating Long COVID, specifically covering Ampligen (rintatolimod) [1] - The company is focused on advancing its pancreatic cancer clinical program while the new patent enhances its intellectual property portfolio and validates Ampligen's potential as a broad-spectrum immunotherapy [2] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The lead product, Ampligen, is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist, demonstrating broad-spectrum activity in clinical trials [4] Clinical Research and Development - Ampligen has shown a broad-spectrum, early-onset antiviral effect by stimulating a strong innate immune response, with data indicating significant decreases in viral replication in SARS-CoV-1 studies [3] - A Phase 2 study (AMP-518) has reported positive topline results, suggesting that Ampligen is generally well tolerated and may reduce fatigue in patients with Long COVID [3]

Core Points - AIM ImmunoTech Inc. will participate in the 2025 Maxim Growth Summit on October 22-23, 2025, in New York, NY, which focuses on industry trends and advancements [1] - Management will be available for in-person one-on-one meetings with registered investors during the conference [2] - AIM ImmunoTech is an immuno-pharma company developing therapeutics for cancers, immune disorders, and viral diseases, with its lead product being Ampligen, currently in Phase 2 clinical trials for metastatic pancreatic cancer in collaboration with AstraZeneca [4] Company Information - AIM ImmunoTech Inc. specializes in research and development of therapeutics targeting multiple diseases, including COVID-19 [4] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist [4] - AIM ImmunoTech is focused on broad-spectrum activity in clinical trials, particularly in combination therapies for cancer treatment [4] Event Information - The Maxim Growth Summit is organized by Maxim Group LLC, a full-service investment banking and wealth management firm based in New York [3] - The summit will feature industry leaders and innovators discussing the latest trends across various sectors [1] - For more details on the summit agenda and AIM's presentation, interested parties can visit the respective websites [2]

Core Insights - AIM ImmunoTech Inc. presented positive progress on its lead program Ampligen for pancreatic cancer at the 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care, highlighting improvements in Progression-Free Survival and Overall Survival from the DURIPANC clinical trial and Early Access Program [1][2][3] Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, with its lead product being Ampligen, a first-in-class investigational drug [5] Clinical Trials and Data - The Phase 2 DURIPANC clinical trial is currently evaluating the combination of Ampligen and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor durvalumab for late-stage metastatic pancreatic cancer patients [3] - The clinical data presented indicates a strong potential for Ampligen in treating late-stage pancreatic cancer, addressing a significant unmet medical need [3] Regulatory and Market Position - Ampligen has patent protection for its combination therapy in the U.S. until 2039 and has received orphan drug designations in both the U.S. and EU, which will provide market protections for an approved drug [3]

Core Insights - AIM ImmunoTech Inc. reported promising mid-year results for Ampligen in combination with AstraZeneca's Imfinzi for pancreatic cancer treatment, showing no significant toxicity and improved progression-free survival (PFS) and overall survival (OS) [1][2] - The company has strengthened its cash position, raising $8.0 million in a public equity offering, which is expected to fund operations for approximately 12 months [10] Financial Highlights - As of June 30, 2025, AIM reported cash, cash equivalents, and marketable investments totaling $835,000 [10] - Research and development expenses for Q2 2025 were $1.2 million, an increase from $1.1 million in Q2 2024 [10] - General and administrative expenses decreased to $1.5 million in Q2 2025 from $2.6 million in Q2 2024 [10] - The net loss from operations for Q2 2025 was $2.8 million, or $(3.68) per share, compared to a net loss of $1.8 million, or $(3.00) per share, in Q2 2024 [10] Clinical Development - The company is prioritizing the development of Ampligen in a Phase 2 trial for locally advanced pancreatic cancer in collaboration with Erasmus Medical Center and AstraZeneca [2] - Positive clinical data has been reported, indicating a clear path toward government approval for Ampligen in treating pancreatic cancer [2] - Upcoming presentations are scheduled at significant cancer research symposiums, highlighting the ongoing research efforts [10]

Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [3] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials [3] Event Announcement - AIM ImmunoTech will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, which will be held virtually from August 19-21, 2025 [1] - The presentation is scheduled for August 20, 2025, at 2:40 PM ET, and will be led by Thomas Equels, the Chief Executive Officer, President & Executive Vice Chairman of the company [1]